Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for IMTX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
June 30, 2026 -0.9257M
March 31, 2026 24.53M
December 31, 2025 115.88M
September 30, 2025 -0.9093M
June 30, 2025 -0.8837M
March 31, 2025 -0.7757M
December 31, 2024 150.60M
September 30, 2024 2.995M
June 30, 2024 -2.140M
March 31, 2024 189.55M
December 31, 2023 -2.107M
September 30, 2023 54.27M
June 30, 2023 39.66M
March 31, 2023 -0.9292M
December 31, 2022
Date Value
September 30, 2022
June 30, 2022 16.95M
March 31, 2022 -0.7729M
December 31, 2021 -0.5974M
September 30, 2021 -0.7641M
June 30, 2021 -1.043M
March 31, 2021 -0.5806M
December 31, 2020 5.034M
September 30, 2020 243.94M
June 30, 2020 -0.6132M
March 31, 2020 -0.6731M
December 31, 2019 -0.5105M
September 30, 2019 -0.5476M
June 30, 2019 -0.497M
March 31, 2019 -0.5064M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
MediGene AG --
InflaRx NV 138.70M
BioNTech SE -126.88M
Moderna, Inc. 14.00M
Intellia Therapeutics, Inc. 196.12M